TNOX Tanox (MM)

HOUSTON, Sept. 14 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) will be among the featured companies presenting at the UBS Global Life Sciences Conference Sept. 25-28 in New York City. Tanox President and Chief Executive Officer Danong Chen, Ph.D., will provide a company update at the conference Sept. 25 at 12:30 p.m., EDT. A live webcast of the presentation will be accessible from the Investor Relations section on the company's Web site at http://www.tanox.com/ . Presentation slides will be available on the site following the live address. About Tanox, Inc. Tanox is a biotechnology company specializing in the development of monoclonal antibodies. The company develops innovative biotherapeutics for the treatment of immune-mediated diseases, inflammation, infectious disease and cancer. Tanox's lead investigational therapy, TNX-355, is a viral-entry inhibitor antibody to treat HIV/AIDS. TNX-355 has shown significant antiviral activity in Phase 2 clinical testing. Tanox's first-approved drug, Xolair(R) (omalizumab), is the first antibody approved to treat moderate-to-severe confirmed, allergic asthma. Xolair was developed in collaboration with Genentech, Inc. and Novartis Pharma AG and is approved for marketing in the United States, Canada and major European countries. Tanox is based in Houston and has a manufacturing facility in San Diego. Additional corporate information is available at http://www.tanox.com/ . http://www.newscom.com/cgi-bin/prnh/20050207/TNOXLOGO DATASOURCE: Tanox, Inc. CONTACT: Steve Sievert of Tanox, Inc., +1-713-578-4211, or Web site: http://www.tanox.com/

Copyright